BOSTON–Mauna Kea Technologies has expanded the international adoption of its Cellvizio imaging platform with new installations at hospitals in Spain and the United Arab Emirates, introducing technology designed to improve the diagnosis and characterization of pancreatic cystic lesions.
The company announced that Centro Médico Teknon in Barcelona has become the first hospital in Spain to deploy Cellvizio for pancreatic cyst evaluation, while King’s College Hospital London in Dubai has become the first hospital in the Middle East and North Africa (MENA) region to offer the technology for this application.
The installations, announced in conjunction with World Pancreatic Cancer Day, represent an expansion of Cellvizio’s use in international healthcare markets.
Pancreatic cancer is the sixth leading cause of cancer-related deaths worldwide, with an estimated 531,000 new cases and nearly 490,000 deaths annually. The disease has a five-year survival rate below 10%, making early detection and accurate diagnosis particularly important.
Pancreatic cysts are frequently discovered incidentally during CT or MRI examinations, affecting an estimated 3% to 10% of adults and as many as 10% to 20% of individuals over age 70.
However, conventional diagnostic methods can struggle to distinguish between benign cysts and those that may develop into cancer. According to the company, up to 30% of pancreatic cysts remain unclassified following endoscopic ultrasound examinations, while more than half of fine-needle aspiration cytology procedures produce inconclusive results.
These diagnostic limitations can lead to unnecessary pancreatic surgeries or prolonged monitoring of patients whose cysts may not pose a significant cancer risk.
Cellvizio uses probe- and needle-based confocal laser endomicroscopy technology to provide real-time microscopic imaging of tissue during endoscopic procedures.
The technique, known as endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE), allows physicians to insert a miniature optical probe through a needle to examine the cellular lining of pancreatic cysts.
Mauna Kea said the technology can differentiate potentially precancerous mucinous lesions from benign cysts with 96% accuracy and may reduce unnecessary surgeries by more than 40%, citing clinical research. The procedure is also included in guidelines issued by the European Society of Gastrointestinal Endoscopy.
At Centro Médico Teknon in Barcelona, the technology is being introduced by Dr. Gonzalo López Roldán, a Gastroenterologist and Endoscopist with ENDOGROUP, the hospital’s advanced endoscopy unit.
The hospital is part of Quirónsalud, Spain’s largest private hospital group, which operates 58 general hospitals, including eight university hospitals.
“Sometimes surgery is recommended early because of the potential risk of malignancy, or patients are kept under unnecessary lifelong surveillance because the diagnosis was not taken as far as it could have been when it was needed. Our aim is to adopt, and use appropriately, techniques such as EUS-nCLE with Cellvizio that provide decisive diagnostic information to help us choose the most suitable strategy in each case. We will also be evaluating artificial intelligence analysis of confocal images to identify lesions with high-grade dysplasia or carcinoma at the right time,” said Dr. López Roldán.
In Dubai, Dr. Farooq Khan, Consultant Hepatologist, Gastroenterologist and Interventional Endoscopist at King’s College Hospital Dubai, is leading the introduction of the technology following regulatory clearance from the UAE’s Emirates Drug Establishment in May 2026.
The hospital operates an Endoscopy Center of Excellence that works alongside its liver transplant, pancreatic surgery and oncology services.
“Conventional imaging often does not give us enough information to determine the nature of an incidentally discovered cyst, whereas examining its lining at a microscopic level during the procedure helps identify patients who need treatment while potentially avoiding unnecessary surgery for benign cysts. In fact, EUS-nCLE has already helped two of our patients who had been under follow-up imaging for several years, enabling us to reach an accurate diagnosis, including a premalignant cyst requiring timely surgery,” said Dr. Khan.
Mauna Kea Technologies said the installations could support broader adoption of Cellvizio across specialized endoscopy centers in Southern Europe and the Middle East.
“These first installations of Cellvizio in Spain and across the MENA region mark a key step in the international expansion of our pancreatic cyst franchise. Partnering with leading clinical teams at Centro Médico Teknon within the Quirónsalud group in Barcelona, and at King’s College Hospital in Dubai shortly after our milestone installation in Abu Dhabi for CellTolerance, reflects growing international demand for real-time cellular imaging while building recurring probe utilization across our newest markets,” said Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies.
The company, which operates in Paris and Boston, develops real-time cellular imaging technologies intended to support the diagnosis and management of gastrointestinal and other medical conditions.


